Arbizu J, García-Ribas G, Carrió I, Garrastachu P, Martínez-Lage P, Molinuevo JL. Recommendations for the use of PET imaging biomarkers in the diagnosis of neurodegenerative conditions associated with dementia: SEMNIM and SEN consensus. Rev Esp Med Nucl Imagen Mol. 2015 Sep-Oct;34(5):303-13. English, Spanish. [Pubmed]
Barkhof F, Hazewinkel M, Binnewijzend M, Smithuis R. Dementia - Role of MRI. Radiology Assistant. Disponible en: [Enlace]
Chételat G, Arbizu J, Barthel H, Garibotto V, Law I, Morbelli S, et al. Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias. Lancet Neurol. 2020 Nov;19(11):951-62. [Pubmed]
Constantinides VC, Paraskevas GP, Paraskevas PG, Stefanis L, Kapaki E. Corticobasal degeneration and corticobasal syndrome: a review. Clin Park Relat Disord. 2019 Aug 30;1:66-71. [Pubmed]
Ferrando R, Damian A. Brain SPECT as a Biomarker of Neurodegeneration in Dementia in the Era of Molecular Imaging: Still a Valid Option? Front Neurol. 2021 May 10;12:629442. [Pubmed]
Groot C, Villeneuve S, Smith R, Hansson O, Ossenkoppele R. Tau PET Imaging in Neurodegenerative Disorders. J Nucl Med. 2022 Jun;63(Suppl 1):20S-26S. [Pubmed]
Harper L, Fumagalli GG, Barkhof F, Scheltens P, O'Brien JT, Bouwman F, et al. MRI visual rating scales in the diagnosis of dementia: evaluation in 184 post-mortem confirmed cases. Brain. 2016 Apr;139(Pt 4):1211-25. [Pubmed]
Illán-Gala I, Falgàs N, Friedberg A, Castro-Suárez S, Keret O, Rogers N, et al. Diagnostic Utility of Measuring Cerebral Atrophy in the Behavioral Variant of Frontotemporal Dementia and Association With Clinical Deterioration. JAMA Netw Open. 2021 Mar 1;4(3):e211290. [Pubmed]
Illán-Gala I, Nigro S, VandeVrede L, Falgàs N, Heuer HW, Painous C, et al. Diagnostic Accuracy of Magnetic Resonance Imaging Measures of Brain Atrophy Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Degeneration. JAMA Netw Open. 2022 Apr 1;5(4):e229588. Erratum in: JAMA Netw Open. 2022 May 2;5(5):e2217977. [Pubmed]
Kim J, Jeong M, Stiles WR, Choi HS. Neuroimaging Modalities in Alzheimer's Disease: Diagnosis and Clinical Features. Int J Mol Sci. 2022 May 28;23(11):6079. [Pubmed]
Kim J, Jeong M, Stiles WR, Choi HS. Neuroimaging Modalities in Alzheimer's Disease: Diagnosis and Clinical Features. Int J Mol Sci. 2022 May 28;23(11):6079. [Pubmed]
Kiymaz T, Khan Suheb MZ, De Jesús O. Progressive Nonfluent Aphasia. Treasure Island (FL): StatPearls Publishing; 2023 Jan. Disponible en: [Enlace]
Lehmann M, Koedam EL, Barnes J, Bartlett JW, Ryan NS, Pijnenburg YA, et al. Posterior cerebral atrophy in the absence of medial temporal lobe atrophy in pathologically-confirmed Alzheimer's disease. Neurobiol Aging. 2012 Mar;33(3):627.e1-627.e12. [Pubmed]
Loreto F, Gontsarova A, Scott G, Patel N, Win Z, Carswell C, et al. Visual atrophy rating scales and amyloid PET status in an Alzheimer's disease clinical cohort. Ann Clin Transl Neurol. 2023 Apr;10(4):619-31. [Pubmed]
Minoshima S, Cross D, Thientunyakit T, Foster NL, Drzezga A. 18F-FDG PET Imaging in Neurodegenerative Dementing Disorders: Insights into Subtype Classification, Emerging Disease Categories, and Mixed Dementia with Copathologies. J Nucl Med. 2022 Jun;63(Suppl 1):2S-12S. Erratum in: J Nucl Med. 2022 Jul;63(7):100-1000. [Pubmed]
Risacher SL, Saykin AJ. Neuroimaging biomarkers of neurodegenerative diseases and dementia. Semin Neurol. 2013 Sep;33(4):386-416. [Pubmed]
Roytman M, Chiang GC, Gordon ML, Franceschi AM. Multimodality Imaging in Primary Progressive Aphasia. AJNR Am J Neuroradiol. 2022 Sep;43(9):1230-43. [Pubmed]
Saito Y, Kamagata K, Wijeratne PA, Andica C, Uchida W, Takabayashi K, et al. Temporal Progression Patterns of Brain Atrophy in Corticobasal Syndrome and Progressive Supranuclear Palsy Revealed by Subtype and Stage Inference (SuStaIn). Front Neurol. 2022 Feb 25;13:814768. [Pubmed]
Schwarz CG. Uses of Human MR and PET Imaging in Research of Neurodegenerative Brain Diseases. Neurotherapeutics. 2021 Apr;18(2):661-72. [Pubmed]
Shams S, Fällmar D, Schwarz S, Wahlund LO, van Westen D, Hansson O, et al. MRI of the Swallow Tail Sign: A Useful Marker in the Diagnosis of Lewy Body Dementia? AJNR Am J Neuroradiol. 2017 Sep;38(9):1737-41. [Pubmed]
Thal DR, Rüb U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002 Jun 25;58(12):1791-800. [Pubmed]
Van Oostveen WM, de Lange ECM. Imaging Techniques in Alzheimer's Disease: A Review of Applications in Early Diagnosis and Longitudinal Monitoring. Int J Mol Sci. 2021 Feb 20;22(4):2110. [Pubmed]
Vemuri P, Decarli C, Duering M. Imaging Markers of Vascular Brain Health: Quantification, Clinical Implications, and Future Directions. Stroke. 2022 Feb;53(2):416-26. [Pubmed]
Young PNE, Estarellas M, Coomans E, Srikrishna M, Beaumont H, Maass A, et al. Imaging biomarkers in neurodegeneration: current and future practices. Alzheimers Res Ther. 2020 Apr 27;12(1):49. [Pubmed]
Yousaf T, Dervenoulas G, Valkimadi PE, Politis M. Neuroimaging in Lewy body dementia. J Neurol. 2019 Jan;266(1):1-26. [Pubmed]